Purpose: To investigate the behavior of tumor subvolumes of high [18F]-fluorodeoxyglucose (FDG) uptake as seen on clinical four-dimensional (4D) FDG-positron emission tomography (PET) scans.
Methods And Materials: Four-dimensional FDG-PET/computed tomography scans from 13 patients taken before radiotherapy were available. The analysis was focused on regions of high uptake that are potential dose-painting targets. A total of 17 lesions (primary tumors and lymph nodes) were analyzed. On each one of the five phases of the 4D scan a classification algorithm was applied to obtain the region of highest uptake and segment the tumor volume. We looked at the behavior of both the high-uptake subvolume, called "Boost," and the segmented tumor volume, called "Target." We measured several quantities that characterize the Target and Boost volumes and quantified correlations between them.
Results: The behavior of the Target could not always predict the behavior of the Boost. The shape deformation of the Boost regions was on average 133% higher than that of the Target. The gross to internal target volume expansion was on average 27.4% for the Target and 64% for the Boost, a statistically significant difference (p < 0.05). Finally, the inhale-to-exhale phase (20%) had the highest shape deformation for the Boost regions.
Conclusions: A complex relationship between the measured quantities for the Boost and Target volumes is revealed. The results suggest that in cases in which advanced therapy techniques such as dose painting are being used, a close examination of the 4D PET scan should be performed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijrobp.2010.08.028 | DOI Listing |
Eur Radiol
January 2025
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Purpose: To evaluate the prognostic value of interim [F]Fluorodeoxyglucose positron emission tomography/computed tomography ([F]FDG PET/CT) after immunotherapy-based systemic therapies in extranodal natural killer/T-cell lymphoma (ENKTL).
Patients And Methods: We retrospectively recruited 133 newly diagnosed nasal-type ENKTL patients who underwent interim [F]FDG PET/CT scans after 2-4 cycles of immunotherapy-based treatments. Interim PET/CT was interpreted by maximum standardized uptake value (SUV), Deauville 5-point scale (DS), and early treatment response.
J Appl Lab Med
January 2025
Eli Lilly and Company, Indianapolis, IN, United States.
Background: Blood-based biomarkers, especially P-tau217, have been gaining interest as diagnostic tools to measure Alzheimer disease (AD) pathology.
Methods: We developed a plasma P-tau217 chemiluminescent immunoassay using 4G10E2 and IBA493 as antibodies, a synthetic tau peptide as calibrator, and the Quanterix SP-X imager. Analytical validation performed in a College of American Pathologists-accredited CLIA laboratory involved multiple kit lots, operators, timepoints, and imagers.
Radiology
January 2025
From the Department of Radiology, University Hospital Halle, Ernst-Grube-Strasse 40, 06120 Halle (Saale), Germany (D.S., J.S., J.M.B.); Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany (L.K., T.W.G., R.K.); Diagnostic Imaging and Pediatrics, Warren Alpert Medical School, Brown University, Providence, RI (K.M.M.); Department of Pediatric Radiology, Imaging and Radiation Oncology, Core-Rhode Island, Providence, RI (K.M.M.); Department of Oncology, St Jude Children's Research Hospital, Memphis, Tenn (J.E.F.); Department of Pediatric Hematology and Oncology, University Hospital Giessen-Marburg, Giessen, Germany (C.M.K., D.K.); Medical Faculty of the Martin Luther University of Halle-Wittenberg, Halle (Saale) Germany (C.M.K.); Department of Radiology, University of Wisconsin-Madison, Madison, Wis (S.Y.C.); Roswell Park Comprehensive Cancer Center, Buffalo, NY (K.M.K.); Department of Radiation Oncology, Medical Faculty of the Martin-Luther-University, Halle (Saale), Germany (T.P., D.V.); Department of Radiation Oncology, Mayo Clinic-Jacksonville, Jacksonville, Fla (B.S.H.); Department of Radio-Oncology, Medical University Vienna, Vienna, Austria (K.D.); and Department of Radiology, Boston Children's Hospital and Harvard Medical School, Boston, Mass (S.D.V.).
Staging of pediatric Hodgkin lymphoma is currently based on the Ann Arbor classification, incorporating the Cotswold modifications and the Lugano classification. The Cotswold modifications provide guidelines for the use of CT and MRI. The Lugano classification emphasizes the importance of CT and PET/CT in evaluating both Hodgkin lymphoma and non-Hodgkin lymphoma but focuses on adult patients.
View Article and Find Full Text PDFCurr Med Chem
January 2025
Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Novel Radiopharmaceuticals and Nanoradiopharmacy, Rio de Janeiro, 21941906, Brazil.
This study discusses the chemical perspectives of the [18F]F-PSMA probe, a pivotal tool in prostate cancer imaging. [18F]Fluorine, a positron emitter with a half-life of 109.8 minutes, is produced in a cyclotron by bombarding [18O]-enriched targets with protons.
View Article and Find Full Text PDFFront Med (Lausanne)
January 2025
Advanced Imaging Research Center, The University of Texas Southwestern Medical Center, Dallas, TX, United States.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!